CEMP +37% on phase-3 data for fusidic acid in skin infections: http://globenewswire.com/news-release/2017/02/24/927445/0/en/Cempra-s-Fusidic-Acid-Achieves-Primary-Endpoint-in-Phase-3-Study-of-ABSSSI.html